Free Trial

Grifols (GRFS) Competitors

Grifols logo
$10.78 +0.08 (+0.75%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.78 0.00 (0.00%)
As of 08/1/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRFS vs. BNTX, SMMT, INSM, TEVA, GMAB, RDY, MRNA, QGEN, VTRS, and ASND

Should you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Qiagen (QGEN), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.

Grifols vs. Its Competitors

Grifols (NASDAQ:GRFS) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grifols$7.81B0.95$169.80M$1.179.21
BioNTech$2.98B8.67-$719.92M-$3.40-31.57

In the previous week, Grifols and Grifols both had 8 articles in the media. BioNTech's average media sentiment score of 0.88 beat Grifols' score of 0.52 indicating that BioNTech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Grifols
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioNTech
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Grifols currently has a consensus price target of $10.30, indicating a potential downside of 4.45%. BioNTech has a consensus price target of $136.58, indicating a potential upside of 27.24%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00
BioNTech
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.76

Grifols has a net margin of 0.00% compared to BioNTech's net margin of -27.37%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.

Company Net Margins Return on Equity Return on Assets
GrifolsN/A N/A N/A
BioNTech -27.37%-3.94%-3.41%

Grifols has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500.

15.5% of BioNTech shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Grifols beats BioNTech on 9 of the 16 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRFS vs. The Competition

MetricGrifolsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.41B$2.50B$5.52B$9.37B
Dividend YieldN/A1.80%4.74%4.12%
P/E Ratio9.218.9728.9323.80
Price / Sales0.95687.56440.5196.33
Price / Cash11.52155.1435.0756.59
Price / Book0.864.838.255.54
Net Income$169.80M$31.62M$3.25B$259.97M
7 Day Performance6.73%-5.28%-3.75%-4.67%
1 Month Performance18.79%3.12%2.99%3.29%
1 Year Performance42.22%-2.00%25.34%17.92%

Grifols Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRFS
Grifols
3.2372 of 5 stars
$10.78
+0.7%
$10.30
-4.5%
+42.2%$7.41B$7.81B9.2123,822Dividend Announcement
BNTX
BioNTech
2.7548 of 5 stars
$108.91
-1.0%
$136.58
+25.4%
+30.9%$26.18B$2.98B-32.036,772Upcoming Earnings
Gap Down
SMMT
Summit Therapeutics
2.89 of 5 stars
$26.34
+0.5%
$34.67
+31.6%
+159.9%$19.56B$700K-77.47110Upcoming Earnings
INSM
Insmed
3.7898 of 5 stars
$102.78
+0.2%
$108.47
+5.5%
+51.4%$19.50B$363.71M-17.271,271Positive News
Upcoming Earnings
TEVA
Teva Pharmaceutical Industries
3.9764 of 5 stars
$16.30
+1.5%
$24.71
+51.7%
-9.5%$18.69B$16.54B-14.1736,830News Coverage
Positive News
Earnings Report
GMAB
Genmab A/S
3.6315 of 5 stars
$21.69
-0.9%
$37.80
+74.3%
-22.9%$13.92B$3.12B12.322,682News Coverage
Positive News
Upcoming Earnings
Short Interest ↑
RDY
Dr. Reddy's Laboratories
2.2883 of 5 stars
$14.57
+0.6%
$16.95
+16.4%
-16.2%$12.16B$3.81B22.0727,811
MRNA
Moderna
4.3952 of 5 stars
$30.97
-0.9%
$46.61
+50.5%
-68.1%$11.98B$3.24B-3.555,800Trending News
Earnings Report
Analyst Forecast
Options Volume
QGEN
Qiagen
3.2031 of 5 stars
$48.06
-0.6%
$49.40
+2.8%
+10.9%$10.68B$1.98B120.495,765News Coverage
Upcoming Earnings
Analyst Upgrade
VTRS
Viatris
2.2069 of 5 stars
$8.90
+0.2%
$10.40
+16.9%
-25.8%$10.45B$14.74B-2.8132,000Upcoming Earnings
Short Interest ↑
ASND
Ascendis Pharma A/S
3.0649 of 5 stars
$168.02
-1.1%
$223.07
+32.8%
+31.9%$10.39B$393.54M0.001,017Analyst Forecast

Related Companies and Tools


This page (NASDAQ:GRFS) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners